Skip to main content
. Author manuscript; available in PMC: 2016 Apr 25.
Published in final edited form as: Vaccine. 2014 May 14;32(30):3780–3786. doi: 10.1016/j.vaccine.2014.05.014

Figure 2.

Figure 2

Impact of vaccination on CMV seroprevalence from natural infection by age group at equilibrium, assuming different ages at vaccination, age-specific duration of infectiousness, 20 year duration of latency, and a vaccine with 70% efficacy, 90% coverage and 5-year duration of protection, United States and Brazil.

Black dots indicate available CMV serological data; U.S. data are from the 1999-2004 National Health and Nutrition Examination Survey [15], data for the age group 0-5 years were not available; Brazilian data are from CMV serological data from Caieiras, Sao Paulo, 1990-1991 [16].